Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216186 | 0.92 | L3MBTL1 (0.39) | ALDH1A1LMNAHTTPKMGAA | |
| SCHEMBL9010034 | 0.86 | PTGS2 (0.38) | ALDH1A1LMNAGAAPTGS2PTGS1 | |
| SCHEMBL9581272 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAGAAMEN1KMT2A | |
| SCHEMBL900004 | 0.82 | GAA (0.38) | ALDH1A1LMNAHTTGAAPTGS2 | |
| SCHEMBL9773406 | 0.81 | CA12 (0.43) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5861877 | 0.81 | AOC2 (0.36) | ALDH1A1HTTPTGS2PTGS1 | |
| SCHEMBL29006523 | 0.81 | PTGS2 (0.45) | PTGS2KDM4EPTGS1 | |
| SCHEMBL8664631 | 0.81 | AOC2 (0.36) | ALDH1A1HTTPTGS2PTGS1 | |
| SCHEMBL16684875 | 0.81 | KMT2A (0.44) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21552592 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNAPKMGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| EP-1924570-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | CHRM3, CHRM2, CHRM1 | ALDH1A1 2263/4885LMNA 3305/4885HTT 3617/4885 |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | ALDH1A1 900/4885LMNA 3821/4885HTT 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.